Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease

Arthritis and Rheumatism

Volumn 60, Issue 7, 2009, Pages 2183-2192

  Richards, Thomas J ^a   Eggebeen, Aaron ^a   Gibson, Kevin ^a   Yousem, Samuel ^a   Fuhrman, Carl ^a   Gochuico, Bernadette R ^b   Fertig, Noreen ^a   Oddis, Chester V ^a   Kaminski, Naftali ^a   Rosas, Ivan O ^c   Ascherman, Dana P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; JO 1 ANTIBODY; MATRIX METALLOPROTEINASE; SIGNAL RECOGNITION PARTICLE;

ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MYOSITIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, INTERSTITIAL; MYOSITIS; POLYMYOSITIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SIGNAL RECOGNITION PARTICLE;

EID: 67650045885     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24631     Document Type: Article

References (41)

1. Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993;100:116-23S.
2. Ascherman DP. Pulmonary complications of inflammatory myopathy. Curr Rheumatol Rep 2002;4:409-14.
3. Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis: a computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985;28:249-55.
4. Dickey BF, Myers AR. Pulmonary disease in polymyositis/dermatomyositis. Semin Arthritis Rheum 1984;14:60-76.
5. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005;17:701-6.
6. Grau JM, Miro O, Pedrol E, Casademont J, Masanes F, Herrero C, et al. Interstitial lung disease related to dermatomyositis: comparative study with patients without lung involvement. J Rheumatol 1996;23:1921-6.
7. Schwarz MI. The lung in polymyositis. Clin Chest Med 1998;19:701-12, viii.
8. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol 1987;14:102-7.
9. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990;141:727-33.
10. Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22.
11. Mielnik P, Wiesik-Szewczyk E, Olesinska M, Chwalinska-Sadowska H, Zabek J. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity 2006;39:243-7.
12. Schnabel A, Reuter M, Biederer J, Richter C, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003;32:273-84.
13. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: a marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983;26:604-11.
14. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006;39:233-41.
15. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004;63:297-301.
16. Tansey D, Wells AU, Colby TV, Ip S, Nikolakoupolou A, du Bois RM, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44:585-96.
17. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008;63:53-9.
18. Fujita J, Ohtsuki Y, Yoshinouchi T, Yamadori I, Bandoh S, Tokuda M, et al. Idiopathic non-specific interstitial pneumonia as an "autoimmune interstitial pneumonia". Respir Med 2005;99:234-40.
19. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5.
20. Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008;59:677-85.
21. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
22. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
24. Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the Myositis Disease Activity Assessment Tool. Arthritis Rheum 2008;58:3593-9.
25. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005;14:981-7.
26. Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000;19:371-7.
27. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56:3125-31.
28. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007;46:1005-8.
29. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
30. Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007;56:1295-303.
31. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990;77:1019-38.
32. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007;19:523-9.
33. Sato S, Hirakata M, Kuwana M, Nakamura K, Suwa A, Inada S, et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 2005;23:609-15.
34. Targoff IN. Idiopathic inflammatory myopathy: autoantibody update. Curr Rheumatol Rep 2002;4:434-41.
35. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006;8:196-203.
36. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992;35:821-30.
37. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.
38. Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med 2008;19:227-35.
39. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004;31:395-404.
40. Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002;129:541-8.
41. Yamadori I, Fujita J, Kajitani H, Bandoh S, Tokuda M, Ohtsuki Y, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int 2001;21:89-93.